Effect of metformin in a novel experimental model of peripheral artery disease
Abstract
Limited drug therapies for peripheral artery disease (PAD)-related walking impairment exist. There has been a recent interest in repurposing the diabetes medication metformin to treat PAD. Animal studies designed to develop new PAD drug therapies have mainly used a model of temporary hind limb ischaemia (HLI). The aim of this study was to test whether metformin improved blood supply and ambulation in a novel mouse model with ongoing HLI. Stable HLI was created in apolipoprotein E-deficient mice by a two-stage surgical procedure. Five days after HLI was induced, mice were randomly allocated to receive metformin (n = 16; 300 mg/kg/day) or vehicle control (n = 15) by oral gavage for four weeks. The primary outcome was hind limb blood supply assessed by laser Doppler. Other outcomes included treadmill performance and molecular changes in the ischaemic limb. Metformin improved hind limb blood supply (P<0.001), but not physical performance, associated with increased phosphorylation of 5′ adenosine monophosphate-activated protein kinase and endothelial nitric oxide synthase (P<0.05), reduced expression of thioredoxin interacting protein (P<0.05) and increased expression of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (P<0.05) in the ischaemic muscles and increased circulating nitric oxide levels (P<0.05). Metformin improved blood supply in a novel model of limb ischaemia associated with molecular changes previously linked with promoting angiogenesis, but…
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.